The impact of FSH receptor polymorphism on time-to-pregnancy: a cross-sectional single-centre study

Birutė Zilaitienė1*, Marius Dirzauskas1, Rasa Verkauskiene1, Rytas Ostrauskas1, Joerg Gromoll2 and Eberhard Nieschlag2

Abstract

Background: Single nucleotide polymorphism of the follicle-stimulating hormone (FSH) receptor (FSHR) is an important marker of ovarian function. However, its role in female fecundity remains debatable. The aim of the study to assess the relationship of FSHR polymorphism of Serine/Serine, Asparagine/Asparagine and Asparagine/Serine variants directly against the time-to-pregnancy (TTP) in women.

Methods: Data were collected from 291 consecutive selected post-partum Caucasians using this criterion: ethnicity, age between 21 and 34-year-old new mothers and, 0–3 days after delivery of newborns in the Klaipeda University Hospital, Lithuania. Questionnaires on factors associated with conception were given to patients, and blood samples were collected for genomic DNA extractions as well as for analysis of follicle-stimulating hormone receptor gene polymorphism. Odds ratios (OR) and 95% confidence intervals (CI) for time-to-pregnancy were estimated by multivariate logistic regression. Women with unplanned pregnancies and those who received assisted reproductive technologies were not included in the study.

Results: After adjustment for other possible factors, increased risk for time-to-pregnancy of 12 or more months was associated with: Serine/Serine polymorphism variant (OR = 1.38, 95% CI 1.56–2.71, p = 0.007), age of 30 or more years (OR = 1.95, 95% CI 1.25–2.71, p = 0.015), gynaecological diseases in the past (OR = 2.21, 95% CI 1.12–5.74, p = 0.027), prior contraception use (OR = 1.87, 95% CI 1.14–3.64, p = 0.016), and fertility problems in the past (OR = 1.57, 95% CI 1.16–4.76, p = 0.019).

Conclusion: The results suggest a possible relationship of FSH receptor gene Serine/Serine variant for the lower possibility of conception during the first 12 months of planned conception.

Keywords: Time to pregnancy, FSH receptor haplotypes, FSH receptor polymorphism

Background

Fecundity is the wonderful biological ability to produce abundant healthy offspring and is affected by genetic and environmental factors [1]. If pregnancy is planned, fertility may be expressed as time-to-pregnancy (TTP) [2]. TTP is defined as the number of contraceptive-free cycles needed to conceive [3]. A TTP greater than 12 months allocates the infertility status [4, 5]. Usually trying to conceive in the first year succeeds for ~ 85% of cases [6].

Impaired fertility is inherited and may be due to inactivating mutations in the gonadotropin and gonadotropin receptor genes [7, 8]. Recent genetic studies have revealed that the pathogenesis of subfertility or infertility can be due to mutations in the follicle-stimulating hormone receptor (FSHR) gene [9]. While mutations affecting FSHR are sporadic; polymorphism of the FSHR gene seems to be a common phenomenon [9]. FSHR inactivating mutations may cause primary or secondary amenorrhea, infertility, and premature ovarian failure [10]; whereas activating mutations can predispose to ovarian hyperstimulation syndrome,
as a consequence of exogenous FSH administration, or to a spontaneous onset [10–12].

In-vitro studies have shown that the A allele at the 29th position in the 5’ untranslated region of the FSHR gene is associated with impaired transcriptional activity [13]. The polymorphism at position 29 in the promoter of the FSHR gene may contribute to the reduced receptor expression [14]. The FSHR shows nucleotide polymorphisms in the promoter and in exon 10 [15]. The single nucleotide polymorphisms in exon 10 results in four discrete allelic variants characterized by the amino acid combinations: threonine (Thr)307-asparagine (Asn)680, alanine (Ala)307-Serine (Ser)680, Ala307-Asn680 and Thr307-Ser680 [15]. The first two allelic variants are very frequent in the Caucasian population [15]. At position 680, three FSH receptor variants are possible: Asn/Asn, Asn/Ser, and Ser/Ser; however, Ser/Ser-680 predominates in the studied infertile population [16].

The studies on FSHR polymorphism, performed on women undergoing in-vitro fertilisation procedures show that women homozygous for the Ser680 variant have higher follicular FSH levels and longer follicular phase length, which suggest a lower sensitivity to FSH. Thus the homozygous Ala307-Ser680 variant is associated with a higher amount of FSH required for ovarian stimulation in women undergoing assisted reproduction [15]. This suggests that the FSHR genotype can influence the ovarian response to FSH stimulation [17, 18]. However, there are studies where this association was not confirmed [19, 20].

FSH is responsible for follicular maturation and for the length and stability of the menstrual cycle [21]. A longer cycle may be associated with more difficulties in conception; women who have the FSHR gene Asn (Asparagine) exchanged for Ser (Serine) at codon 680 have statistically proven longer menstrual cycles [22].

Despite the numerous publications on the FSHR polymorphism impact on women's reproductive function; an FSHR polymorphic relationship to TTP has not yet been studied. Here we aimed to assess the relationship of the FSHR polymorphism Serine/Serine, Asparagine/Asparagine and Asparagine/Serine variants on TTP in a sample of Lithuanian women.

**DNA sampling**

A venous blood sample was drawn for DNA extraction from all 291 participants.

**DNA extraction** was performed in a certificated “SORPO” laboratory of Thermo Fisher Scientific Inc. in Vilnius, Lithuania. DNA samples froze at-20 °C; were sent to the University of Munster in Germany. There are two known polymorphisms of clinical relevance in the hormone (FSH) receptor exon 10: Ala or Thr at position 307 (dbSNP numbers 6165), and Asn or Ser at position 680 (dbSNP numbers 6166). These give rise to two discrete allelic variants: Thr307/Asn680 and Ala307/Ser680. The allelic variants at codon 307 and 680 are almost invariably associated, therefore codon 680 was assessed, and all women were classified as homozygous (Ser/Ser or Asn/Asn) or heterozygous (Asn/Ser).

Genomic DNA was extracted from peripheral blood using a FlexiGene DNA extraction kit (QIAGEN, Hilden, Germany) according to the manufacturer's instruction. All samples were screened for the single nucleotide polymorphism (SNP) at position 2039 (codon 680) of exon 10 by the TaqMan allelic discrimination assay while using the ABI Prism 7000 sequence detection system (Applied Biosystems, Darmstadt, Germany). The probes (SNP indicated in **bold lower case letters**) were 5’-AGAGTCACC AgTGGTT-3’ (6-carboxyfluorescein ﬂuorescence) and 5’-AGTCACCAdTGGTTC-3’ (VIC ﬂuorescence). The
primers were 5′-AAGGAATG GCCACTGCTTTC-3′ (forward) and 5′-GGGGTAATG ACTTAGAGGGACAA -3′ (reverse). Each polymerase chain reaction (PCR) (25 μl) contained: 2 μl DEPC-treated water, 12.5 μl Universal master mix, 0.25 μl of each probe, and 4.5 μl of each primer (5 pmoI). Using the TaqMan assay, PCR was performed in two steps: absolute quantification and allelic discrimination. For absolute quantification, the cycles were as follows: stage 1: Probe binding at 50 °C for 2 mins (1 cycle); stage 2: denaturation at 95 °C for 10 mins (1 cycle), followed by 35 cycles at 95 °C for 15 s; stage 3:60 °C for 1 min. Whereas the allelic discrimination assay took 1 min at 60 °C.

Statistical analysis
Analyses were performed using SPSS 17.0 software. Women who conceived after ≥12 months of trying were classified as the risk group. The normality of distribution was tested using the Kolmogorov-Smirnov test. Student normal distribution dependence between qualitative features performed by comparing multiple pairs. For evaluating Kruskal-Wallis test was performed. Bonferroni test was and nonparametric dispersive analysis with ANOVA and difference between more than two groups; parametric used in skewed distributions. In order to determine the mal distributions, and the Mann-Whitney (U) test was (t) criterion was used for comparison of means for nor-

Results
FSHR genetic variants
The mean TTP in the study group of 291 woman was 5.3 ± 10.9 (median [25–75%]: 1.0 [1.0–5.0]) months. The main demographic, social, lifestyle and other characteristics of the participants are shown in Table 1.

During FSH receptor genotype analysis three groups of Asn680 and Ser680 variation were detected: 101 (34.7%) of cases were found to be homozygous for Asn680 (Asn/Asn -group), 148 (50.9%) heterozygous for Asn680 and Ser680 (Asn/Ser -group), and 42 (14.4%) homozygous for Ser680 (Ser/Ser -group). Median TTP in the Asn/Asn participant group was 1.0 [95% CI 1.0–4.0] months, in the Asn/Ser group: 1.0 [1.0–3.75] months, and in the Ser/Ser group: 7.0 [1.0–15.25] months. Furthermore, these differences were of significant (p < 0.03).

Women having the Ser/Ser polymorphism variant had significantly longer TTP compared to those bearing vari-

Risk factors for a TTP of 12 or more months for the women in the study group
Logistic regression methods were used to explore potential risk factors for longer TTP. Proportional differences were analysed to compare data of women who conceived up till 12 months with data of women who conceived at 12 or more months. Meanwhile, other factors possibly having an influence on TTP were also checked in this study. Most of the study participants were living in the city, in their own residences, as couples had higher education, higher monthly salary, worked, didn’t smoke, and drank coffee (Table 1). Only a few of cases were obese (5.50%), had previous gynaecological diseases (15.46%), or fertility problems (5.84%). Respondents with alcohol consumption reported stress during pregnancy planning and pregnancy quantity; both divided up equally. The use of folic acid or other food supplements was surprisingly low (24.40 and 33.33% respectively). TTP of ≥12 months was reported significantly more often by women whose age was 30 years or more (p = 0.048), who had irregular menstrual cycles (p < 0.001), previous fertility problems and/or gynaecological diseases (p < 0.001 both), used any contraception prior to pregnancy planning (p = 0.004), drank coffee (p = 0.048), consumed other food supplements (p = 0.004), lived within < 10 km from factories (p = 0.04), had low physical activity (p = 0.044), and the SER/SER polymorphism variant (p < 0.001). Unadjusted univariate OR and 95% CI for
conceiving after 12 or more months with the presence of previously mentioned factors are presented in Table 4.

Coffee consumption and low physical activity correlated significantly with fertility problems in the past ($r = 0.2; p = 0.001$ and $r = 0.23; p = 0.013$ respectively); meanwhile, irregular menstrual cycles correlated with FSHR gene Ser/Ser variant ($r = 0.17; p = 0.008$); a ≥ 560 EURO monthly salary and the use of other food additives – with older age ($r = 0.17; p = 0.008$ and $r = 0.27; p = 0.03$ respectively); as well as living < 10 km from factories, which correlated with gynaecological diseases ($r = 0.18; p = 0.009$); therefore, these factors were excluded from further analysis. The use of contraception prior to pregnancy planning showed no correlation to other factors

Table 1 Main characteristics of study participants

| Criteria | FSHR genetic variant |
|----------|----------------------|
|          | Asn/Asn | Asn/Ser | Ser/Ser |
|          | n | % or Median (25–75% CI) | n | % or Median (25–75% CI) | n | % or Median (25–75% CI) |
| Participants | 101 | 34.7 | 148 | 50.9 | 42 | 14.4 |
| Mean age (years) | 27.4 ± 5.9 | 27.2 ± 5.5 | 27.9 ± 5.0 |
| Median body mass index (kg/m$^2$) | 21.4 (19.8–24.1) | 22.3 (20.0–24.1) | 21.5 (20.1–23.1) |
| Median TTP (month) | 1.0 (1.0–4.0)* | 1.0 (1.0–3.8)* | 7.0 (1.0–15.3) |
| TTP < 12 month | 92 | 91.1* | 133 | 89.9* | 27 | 64.3 |
| TTP ≥ 12 month | 9 | 8.9 | 15 | 10.1 | 15 | 35.7 |
| Nuliparous | 48 | 47.5 | 75 | 50.7 | 25 | 59.5 |
| Multiparous | 53 | 52.5 | 73 | 49.3 | 17 | 40.5 |
| Living in the city | 76 | 75.3 | 115 | 77.7 | 35 | 83.3 |
| Living in the country | 25 | 24.7 | 33 | 22.3 | 7 | 16.7 |
| Education lower than college | 37 | 36.6 | 63 | 42.6 | 14 | 33.3 |
| College education and higher | 64 | 63.4 | 85 | 57.4 | 28 | 66.7 |
| Salary < 560 Euro/month | 34 | 33.7 | 36 | 24.3 | 11 | 26.2 |
| Salary ≥ 560 Euros/month | 67 | 66.3 | 112 | 75.7 | 31 | 73.8 |
| Smoking | 28 | 27.7 | 28 | 18.9 | 6 | 14.3 |
| Alcohol consumers | 51 | 50.5 | 74 | 50.0 | 20 | 47.6 |
| Coffee consumption | 27 | 26.7* | 37 | 25.0* | 32 | 76.2 |
| Folic acid use | 24 | 23.8 | 36 | 24.3 | 11 | 26.2 |
| Use of other food additives | 32 | 31.7 | 50 | 33.8 | 14 | 33.3 |
| Physical activity/sports | 28 | 27.7 | 48 | 32.4 | 16 | 38.1 |
| Prior hormonal contraception use | 26 | 25.7 | 31 | 20.9 | 10 | 23.8 |
| Regular menstrual cycle | 68 | 67.3* | 113 | 76.4* | 17 | 40.5 |
| Irregular menstrual cycle | 33 | 32.7* | 35 | 23.6* | 25 | 59.5 |
| Sexual intercourse one time/week | 18 | 17.8 | 27 | 18.2 | 7 | 16.7 |
| Sexual intercourse 2 times and more/week | 83 | 82.2 | 121 | 81.8 | 35 | 83.3 |
| Past fertility problems | 8 | 7.9 | 6 | 4.0 | 3 | 7.1 |
| Gynaecological diseases in the past | 3 | 3.0 | 4 | 2.7 | 1 | 2.4 |
| Working status | 93 | 92.1 | 141 | 95.3 | 39 | 92.9 |
| Stress | 60 | 59.4 | 55 | 37.2 | 21 | 50.0 |
| Use of pesticides | 2 | 1.9 | 1 | 0.7 | 1 | 2.4 |

n – number of study participants; *p < 0.05 compared with the Ser/Ser group. For quantitative variables p value by non-parametric ANOVA (Kruskal Wallis), for qualitative variables p value by $\chi^2$ test.
from the univariate regression model. The evaluation of significant correlations was done using the Forward Stepwise likelihood ratio method and was referenced to the database. This algorithm converged through 3 steps; selecting: older age (≥30 years), the use of any contraception prior to pregnancy planning, previous fertility problems, gynaecological diseases, and the Ser/Ser polymorphism. These were the most significant factors that correctly predicted TTP of 12 or more months (positively classified prognosis was 91.1%). The combination of these factors formed the multivariate logistic regression model (Table 5). All independent variables were included in the analysis (older age, irregular menstrual cycle, past fertility problems, gynaecological diseases, use of contraception prior to conception, living < 10 km from factories, and having Ser/Ser polymorphism variant); however, the Forward Stepwise Likelihood ratio method selected the 5 most significant ones (stated above). Accordingly, older age (≥30 years), use of any contraception prior to conception, and having gynaecological diseases increased the OR of conceiving after 12 or more months almost by double; having fertility problems in the past: 1.5 times, and if Ser/Ser polymorphism is present: 1.7 times.

**Discussion**

The FSHR polymorphism’s impact on women’s reproductive function has been demonstrated in several studies [9, 11, 16, 17, 23]; particularly in some diseases, such as the polycystic ovary syndrome and amenorrhea [24–26]. Some investigations provide contradictory data on the relationship between single nucleotide polymorphisms, and their link to polycystic ovary syndrome and amenorrhea [27–29]. The main reported findings on changes of hormonal dynamics in women with homozygote mutated Ser680 throughout the menstrual cycle were with lower serum levels of estradiol, progesterone and inhibin A [22]. However, these women had significantly higher FSH levels, and longer menstrual cycles [12, 14, 18]. Patients with the Ser680/Ser680 genotype are more resistant to FSH action and thus require a stronger stimulus for the same biological response [22]. This finding is important in infertility treatment; patients with the homozygous FSHR Ser680/Ser680 polymorphism have double the chance of having a resistance to clomiphene citrate [30]. They require higher FSH dosages in order to show the same estradiol response during controlled ovarian stimulation [24]. Furthermore, it was also demonstrated that the frequency of Ser680/Ser680 variation in the control population is lower than if compared to the infertile women’s group [23]. Thus it may be hypothesised that the Ser680/Ser680 genotype could be directly related to a women’s fertility. To our knowledge, the FSHR polymorphism was never investigated in direct relation

---

**Table 2** Estimated odds ratios for TTP ≥12 months for FSHR genetic variants

|            | OR   | 95% CI       | P-value |
|------------|------|--------------|---------|
| Ser/Ser vs. Asn/Asn | 5.68 | 4.83–6.70   | < 0.0001 |
| Ser/Ser vs. Asn/Ser | 4.93 | 4.28–5.68   | < 0.0001 |
| Ser/Ser vs. Asn/Asn + Asn/Ser | 5.21 | 4.65–5.85 | < 0.0001 |

OR – odds ratio, p – significance level
to TTP in a fertile population. In this study, women were considered to be fertile if they achieved pregnancy without using assisted reproductive technology methods. A large number of factors possibly affecting TTP were investigated along with the FSHR polymorphism in order to detect independent factors predicting longer TTP and to establish the role of FSHR polymorphism between other determinants of women’s fertility.

Our data confirmed that higher age, previous gynaecological diseases, and/or fertility problems pose as risk factors for longer TTP. An association for the risk of longer TTP due to hormonal contraception use prior to conception is more questionable. However, an older age of women using contraception could be the reason for this finding.

The relationship of the FSHR polymorphism to the length of the menstrual cycle was demonstrated in our study, as well as in previous publications [22]. Differences in menstrual cycle length between the Ser680/Ser680 and the Asn680/Asn680 groups result in 12.5 vs. 13.5 menstrual cycles per year, respectively [22]. Assuming no difference in age at the time of menopause; women with the Ser680/Ser680 genotype would experience 30–40 cycles fewer, than women with an Asn680/Asn680 genotype during their reproductive life [22]. Some authors conclude that women with the Ser680/Ser680 genotype have a lower chance to achieve pregnancy during the same time period if compared to the other variants [23, 30]. Therefore, menstrual periods are stressful events that have certain disadvantages; such as blood loss, menstrual discomfort, and the effects of hormone fluctuations on mood, breast and other oestrogen-dependent organs. This gives rise to some speculation that fewer menstrual cycles during the reproductive lifespan might represent an evolutionary advantage and might influence fertility positively [22]. Our data provide direct evidence that women with the Ser680/Ser680 genetic variant had a lower chance of conception than females with Asn680/Asn680 and Asn680/Ser680 genetic variants.

We have demonstrated that the FSH receptor gene Serine/Serine variant polymorphism is associated with a fivefold lower likelihood to become pregnant during the first 12 months of attempts to conceive.

The other independent factors predicting a TTP of 12 or more months in the study group were older age, gynaecological diseases, fertility problems in the past, and the use of contraception prior to conception.

Some limitations of our study, especially related to the retrospective design, should be discussed. A retrospective design of the study was used in order to achieve a higher participation rate. Only one polymorphism in this region was evaluated, and furthermore, no replication in an independent cohort was attempted. However, it was previously demonstrated that immediately after delivery women can recall the period before conception very well, so data reported here can be treated as reliable [2]. Because of the selected study design, it was not possible to include women who had miscarriages, ectopic pregnancies, or an induced abortion; as well as, to collect information on other important factors that may affect TTP, such as basal FSH levels and semen quality. Moreover, the study was conducted in only one region of the country, which represents one quarter of the entire Lithuanian female population.

Table 3 Prognostic value of FSHR polymorphism variants for TTP < 12 vs. ≥12 months

| Variable                                      | Sensitivity (%) | Specificity (%) | Prognostic value Positive (%) | False rate Positive (%) | p-value |
|-----------------------------------------------|----------------|----------------|------------------------------|-------------------------|---------|
| Ser/Ser vs. Asn/Asn                           | 62.50          | 77.31          | 65.71                        | 8.91                    | 0.0001  |
| Ser/Ser vs. Asn/Ser                          | 50.00          | 83.13          | 49.15                        | 10.14                   | 0.0399  |
| Ser/Ser vs. Asn/Asn + Asn/Ser                | 38.46          | 89.29          | 54.78                        | 9.64                    | 0.007   |

(Continued...)

Table 4 Univariate odds ratios for TTP ≥12 months in the group of women analysed for FSHR polymorphism

| Variables                                  | OR      | 95% CI     | p       |
|--------------------------------------------|---------|------------|---------|
| Past fertility problems                    | 6.97    | 6.22–7.82  | < 0.0001|
| Prior contraception use                    | 6.43    | 5.74–7.22  | 0.0043  |
| Irregular menstrual cycle                  | 4.24    | 3.79–4.77  | < 0.0001|
| Gynaecological diseases in the past         | 3.44    | 3.07–3.86  | 0.0009  |
| Living 10 or less km from factories        | 2.06    | 1.84–2.32  | 0.0399  |
| Age 30 years and older                     | 1.31    | 1.17–1.47  | 0.0477  |
| Ser/Ser polymorphism variant               | 5.20    | 2.45–11.05 | 0.0004  |

(Continued...)

Table 5 A multivariate stepwise Enter model describing significant factors for TTP ≥12 months in the group of women analysed for the FSHR polymorphism

| Variables                                  | OR      | 95% CI     | p-value |
|--------------------------------------------|---------|------------|---------|
| Past fertility problems                    | 1.568   | 1.16–4.76  | 0.019   |
| Prior contraception use                    | 1.871   | 1.14–3.64  | 0.016   |
| Gynaecological diseases in the past         | 2.212   | 1.12–5.74  | 0.027   |
| Age 30 years and older                     | 1.952   | 1.25–2.71  | 0.015   |
| Ser/Ser polymorphism variant               | 1.678   | 1.56–2.71  | 0.007   |

Constant = 3.741
Strengths and limitations of this study

- The FSH receptor gene polymorphism may affect human reproduction by causing menstrual cycle disorders.
- The present study demonstrates the effect of FSH receptor gene polymorphism on time to pregnancy that has not been investigated till now.
- The relationship of FSHR Serine680/Serine680 variant polymorphism to lower fecundity can have clinical relevance; e.g. more conservative infertility management can be suggested for women with unexplained infertility having this genetic variant.
- Further studies including prospective studies on the impact of genetic factors on women’s fertility are needed.

Conclusions

Further studies including prospective studies on the impact of genetic factors on women’s fertility are needed. Comprehensively study the effects of FSHR polymorphisms on various reproductive traits, the most studied rs6166 SNP should be evaluated together with the rs1394205 in the 5′UTR and with the SNPs in the FSHB locus [31]. However, it is already clear that the relationship of FSHR Ser680/Ser680 variant polymorphism to lower fecundity can have clinical relevance; e.g. more conservative infertility management can be suggested for women with unexplained infertility whose have this genetic variant.

Abbreviations

5′UTR: 5′ untranslated region; Ala: Alanine; Asp: Asparagine; Ct: Confidence interval; FSH: Follicle-stimulating hormone; FSHB: Follicle-stimulating hormone beta subunit; FSHR: Follicle-stimulating hormone receptor; OR: Odds ratios; Ser: Serine; SNP: Single-nucleotide polymorphism; Thr: Threonine; TTP: Time-to-pregnancy

Acknowledgements

We hereby express sincere thanks to the staff of the Klaipeda University Hospital for affable conditions for our study. Susan Nieschlag, M.A. deserves special thanks for language editing of the manuscript. We appreciate the ultimate English grammar correction by Mr. Arnold Kincius.

Availability of data and materials

The original data set is available on individual request by emailing the corresponding author, birute.zilaitiene@lsmuni.lt.

Authors’ contributions

MD, JG, EN, BZ, RV, and RO were involved in the concept and design. MD, JG, EN, and BZ performed the analyses and MD, JG, EN, RV, and RO contributed to the interpretation of the data. MD, BZ and RO drafted the manuscript, and JG, EN and RV provided critical revision. MD, JG, EN, BZ, RV, and RO were involved in the final approval. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the Lithuanian Bioethics Committee (21/12/2006 No. 59/2). The aim of the survey protocol was carefully explained to each subject of study entry, and a written informed consent was obtained.

Consent for publication

Not applicable.

Competing interests

All authors declare that they have no competing interest. The authors alone are responsible for the content and writing of the paper.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Institute of Endocrinology, Lithuanian University of Health Sciences, 50009 Kaunas, Lithuania. 2Center of Reproductive Medicine and Andrology, University of Münster, 48149 Münster, Münster, Germany.

Received: 13 February 2017 Accepted: 21 June 2018
Published online: 28 June 2018

References

1. Caserta D, Mantovani A, Maro R, Fazi A, Ciardo F, La Rocca C, et al. Environment and women’s reproductive health. Hum Reprod Update. 2011; 17(3):418–33. https://doi.org/10.1093/humupd/dmq61.
2. Joffe M. Feasibility of studying subfertility using retrospective self reports. J Epidemiol Community Health. 1989;43(3):268–74.
3. Baird DD, Wilcox AJ, Weinberg CR. Use of time to pregnancy to study environmental exposures. Am J Epidemiol. 1986;124(3):470–80.
4. Schmidt L, Holstein BE, Christensen U, Bolvin J. Communication and coping as predictors of fertility problem stress: cohort study of 816 participants who did not achieve a delivery after 12 months of fertility treatment. Hum Reprod. 2005;20(1):3248–56.
5. Stanford JB, Dunson DB. Effects of sexual intercourse patterns in time to pregnancy studies. Am J Epidemiol. 2007;165(9):1088–95.
6. Gnoth C, Godehardt E, Frank-Hermann P, Friol K, Tiggges J, Freundl G. Definition and prevalence of subfertility and infertility. Hum Reprod. 2005; 20(5):1144–7. https://doi.org/10.1093/humrep/deh780.
7. Huhtaniemi IT,Themmen AP. Mutations in human gonadotropin and gonadotropin-receptor genes. Endocrine. 2005;26(3):207–17.
8. Latorrico AC, Anhold U. Gonadotropin resistance. Endocr Dev. 2013;24:25–32. https://doi.org/10.1159/000342696.
9. Levallet J, Palarinen P, Huhtaniemi IT. Follicle-stimulating hormone ligand and receptor mutations, and gonadal dysfunction. Arch Med Res. 1999;30(6):486–94. https://doi.org/10.1007/s00018-012899/00355-8.
10. MussiA C, Guani B, Mari C, Restagno G, Massobrio M, Revelli A. Mutations and polymorphisms of the FSH receptor (FSHR) gene: clinical implications in female fecundity and molecular biology of FSHR protein and gene. Obstet Gynecol Surv. 2008;63(12):785–95. https://doi.org/10.1097/OGS.0b013e31819574b7.
11. Lauin M, Grigorova M, Huhtaniemi IT. Pharmacogenetics of follicle-stimulating hormone action. Curr Opin Endocrinol Diabetes Obes. 2012; 19(3):220–7. https://doi.org/10.1097/MED.0b013e328353ed11.
12. Achrekar SK, Modi DN, Meherji PK, Patel ZM, Mahale SD. Follicle stimulating hormone receptor gene variants in women with primary and secondary amenorrhea. J Assist Reprod Genet. 2010;27(6):317–26. https://doi.org/10.1007/s10815-010-9404-9.
13. Achrekar SK, Modi DN, Desai SK, Mangoli VS, Mangoli RV, Mahale SD. Poor ovarian response to gonadotrophin stimulation is associated with FSH receptor polymorphism. Reprod Biomed Online. 2009;18(4):509–15.
14. Desai SS, Achrekar SK, Pathak BR, Desai SK, Mangoli VS, Mangoli RV, et al. Follicle-stimulating hormone receptor polymorphism (G-29A) is associated with altered level of receptor expression in granulosa cells. J Clin Endocrinol Metab. 2011;96(9):2805–12. https://doi.org/10.1210/jc.2011-1064.
15. Simoni M, Nieschlag E. Gromoll J. Isofoms and single nucleotide polymorphisms of the FSH receptor gene: implications for human reproduction. Hum Reprod Update. 2002;8(5):413–21.
16. Falconer H, Anderson E, Aanesen A, Fried G. Follicle-stimulating hormone receptor polymorphisms in a population of infertile women. Acta Obstet Gynecol Scand. 2005;84(8):806–11.
17. de Koning CH, Benjamin T, Harm H, Hornburg R, van Montfrans JM, Gromoll J, et al. The distribution of FSH receptor isoforms is related to basal
FSH levels in subfertile women with normal menstrual cycles. Hum Reprod. 2006;21(2):443-6.

18. Altmäe S, Hovatta O, Staveurs-Evers A, Salumets A. Genetic predictors of controlled ovarian hyperstimulation: where do we stand today? Hum Reprod Update. 2011;17(6):813–28. https://doi.org/10.1093/humupd/dmr034.

19. Genro VK, Matte U, De Conto E, Cunha-Filho JS, Fanchin R. Frequent polymorphisms of FSH receptor do not influence antral follicle responsiveness to follicle-stimulating hormone administration as assessed by the follicular output RaTe (FORT). J Assist Reprod Genet. 2012;29(7):657–63. https://doi.org/10.1007/s10815-012-9761-7.

20. Klinkert ER, te Velde ER, Weima S, van Zandvoort PM, Hanssen RG, Nilsson PR, et al. FSH receptor genotype is associated with pregnancy but not with ovarian response in IVF. Reprod BioMed Online. 2006;13(5):687–95. https://doi.org/10.1016/S1472-6483(10)60660-8.

21. Son WY, Das M, Shalom-Paz E, Holzer H. Mechanisms of follicle selection and development. Minerva Ginecol. 2011;63(2):89–102.

22. Greb RR, Grishaber K, Grönnoli J, Sonntag B, Nieschlag E, Kiesel L, et al. A common single nucleotide polymorphism in exon 10 of the human follicle stimulating hormone receptor is a major determinant of length and hormonal dynamics of the menstrual cycle. J Clin Endocrinol Metab. 2005;90(8):4866–72.

23. Laven JS, Mulders AG, Suryandari DA, Grönnoli J, Nieschlag E, Fauser BC, et al. Follicle-stimulating hormone receptor polymorphisms in women with normogonadotrophic anovulatory infertility. Fertil Steril. 2003;80(4):986–92.

24. Simoni M, Tempfer CB, Destenaves B, Fauser BC, Functional genetic polymorphisms and female reproductive disorders: part I: polycystic ovary syndrome and ovarian response. Hum Reprod Update. 2008;14(5):459–84. https://doi.org/10.1093/humupd/dmr024.

25. Nakamura Y, Maekawa R, Yamagata Y, Tamura I, Sugino N. A novel mutation in exon8 of the follicle-stimulating hormone receptor in a woman with primary amenorrhea. Gynecol Endocrinol. 2008;24(12):708–12. https://doi.org/10.1080/09513590802454927.

26. Gu BH, Park JM, Bae KH. Genetic variations of follicle stimulating hormone receptor are associated with polycystic ovary syndrome. Int J Mol Med. 2010;26(1):107–12.

27. Du J, Zhang W, Guo L, Zhang Z, Shi H, Wang J, et al. Two FSHR variants, haplotypes and meta-analysis in Chinese women with premature ovarian failure and polycystic ovary syndrome. Mol Genet Metab. 2010;100(3):292–5. https://doi.org/10.1016/j.ymgme.2010.03.018.

28. Unsal T, Konac E, Yesilkaya E, Yilmaz A, Bideci A, Ilke Onen H, et al. Genetic polymorphisms of FSHR, CYP17, CYP1A1, CAPN10, INSR, SERPINE1 genes in adolescent girls with polycystic ovary syndrome. J Assist Reprod Genet. 2009;26(4):205–16. https://doi.org/10.1007/s10815-009-9308-6.

29. Tong Y, Liao WX, Roy AC, Ng SC. Absence of mutations in the coding regions of follicle-stimulating hormone receptor gene in Singapore Chinese women with premature ovarian failure and polycystic ovary syndrome. Horm Metab Res. 2001;33(4):221–6.

30. Overbeek A, Kuiper EA, Hendriks ML, Blankenstein MA, Ketel IJ, Twisk JW, et al. Clomiphene citrate resistance in relation to follicle-stimulating hormone receptor Ser680Ser-polymorphism in polycystic ovary syndrome. Hum Reprod. 2009;24(8):2007–13. https://doi.org/10.1093/humrep/dep114.

31. Simoni M, Casarini L. Mechanisms in endocrinology: genetics of FSH action: a 2014-and-beyond view. Eur J Endocrinol. 2014;170(3):R91–107. https://doi.org/10.1530/EJE-13-0624.